CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
2.130
+1.202 (129.43%)
At close: May 12, 2025, 4:00 PM
2.170
+0.040 (1.88%)
Pre-market: May 13, 2025, 9:18 AM EDT
CytomX Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | 47.6 | 38.05 | 17.17 | 193.65 | 205.53 | 191.86 | Upgrade
|
| Short-Term Investments | 32.28 | 62.57 | 157.34 | - | 99.7 | 124.26 | Upgrade
|
| Cash & Short-Term Investments | 79.89 | 100.62 | 174.51 | 193.65 | 305.23 | 316.12 | Upgrade
|
| Cash Growth | -46.84% | -42.34% | -9.88% | -36.55% | -3.45% | 6.74% | Upgrade
|
| Receivables | 1.96 | 3.1 | 3.43 | 35.99 | 0.79 | 0.8 | Upgrade
|
| Prepaid Expenses | 4.79 | 3.58 | 5 | 7.47 | 4.29 | 7.1 | Upgrade
|
| Total Current Assets | 86.63 | 107.31 | 182.94 | 237.1 | 310.3 | 324.01 | Upgrade
|
| Property, Plant & Equipment | 9.28 | 10.6 | 16.18 | 21.02 | 25.32 | 29.45 | Upgrade
|
| Goodwill | 0.95 | 0.95 | 0.95 | 0.95 | 0.95 | 0.95 | Upgrade
|
| Other Intangible Assets | 0.55 | 0.58 | 0.73 | 0.88 | 1.02 | 1.17 | Upgrade
|
| Other Long-Term Assets | 1.09 | 1.09 | 1 | 0.94 | 1.82 | 3.09 | Upgrade
|
| Total Assets | 98.5 | 120.53 | 201.79 | 260.89 | 339.41 | 358.66 | Upgrade
|
| Accounts Payable | 0.28 | 1.09 | 1.46 | 2.81 | 2.82 | 3 | Upgrade
|
| Accrued Expenses | 11.41 | 12.34 | 17.6 | 22.82 | 30.62 | 19.86 | Upgrade
|
| Current Portion of Leases | 5.29 | 5.15 | 4.59 | 4.08 | 3.62 | 3.2 | Upgrade
|
| Current Unearned Revenue | 33.23 | 67.2 | 132.27 | 121.27 | 40.82 | 42.06 | Upgrade
|
| Other Current Liabilities | - | - | - | 1.63 | - | - | Upgrade
|
| Total Current Liabilities | 50.2 | 85.77 | 155.91 | 152.61 | 77.87 | 68.11 | Upgrade
|
| Long-Term Leases | 2.86 | 4.24 | 9.39 | 13.98 | 18.06 | 21.68 | Upgrade
|
| Long-Term Unearned Revenue | 16.21 | 26.86 | 80.05 | 180.06 | 243.94 | 276.65 | Upgrade
|
| Other Long-Term Liabilities | 4.18 | 4.12 | 3.89 | - | - | - | Upgrade
|
| Total Liabilities | 73.45 | 120.99 | 249.24 | 346.64 | 339.87 | 366.44 | Upgrade
|
| Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Additional Paid-In Capital | 693.1 | 691.1 | 675.91 | 637.12 | 623.34 | 499.96 | Upgrade
|
| Retained Earnings | -668.05 | -691.58 | -723.45 | -722.88 | -623.56 | -507.69 | Upgrade
|
| Comprehensive Income & Other | -0 | 0.03 | 0.1 | 0.01 | -0.24 | -0.05 | Upgrade
|
| Total Common Equity | 25.05 | -0.46 | -47.45 | -85.75 | -0.46 | -7.77 | Upgrade
|
| Shareholders' Equity | 25.05 | -0.46 | -47.45 | -85.75 | -0.46 | -7.77 | Upgrade
|
| Total Liabilities & Equity | 98.5 | 120.53 | 201.79 | 260.89 | 339.41 | 358.66 | Upgrade
|
| Total Debt | 8.15 | 9.39 | 13.97 | 18.06 | 21.67 | 24.87 | Upgrade
|
| Net Cash (Debt) | 71.74 | 91.24 | 160.54 | 175.59 | 283.55 | 291.25 | Upgrade
|
| Net Cash Growth | -47.79% | -43.17% | -8.58% | -38.07% | -2.64% | 8.49% | Upgrade
|
| Net Cash Per Share | 0.84 | 1.08 | 2.18 | 2.67 | 4.42 | 6.31 | Upgrade
|
| Filing Date Shares Outstanding | 87.12 | 80.1 | 67.72 | 66.23 | 65.39 | 64.78 | Upgrade
|
| Total Common Shares Outstanding | 87.12 | 80.1 | 67.31 | 66.23 | 65.39 | 48.25 | Upgrade
|
| Working Capital | 36.43 | 21.53 | 27.02 | 84.49 | 232.43 | 255.9 | Upgrade
|
| Book Value Per Share | 0.29 | -0.01 | -0.70 | -1.29 | -0.01 | -0.16 | Upgrade
|
| Tangible Book Value | 23.55 | -1.99 | -49.13 | -87.58 | -2.43 | -9.89 | Upgrade
|
| Tangible Book Value Per Share | 0.27 | -0.02 | -0.73 | -1.32 | -0.04 | -0.20 | Upgrade
|
| Machinery | - | 16.69 | 16.3 | 17 | 17.75 | 16.4 | Upgrade
|
| Construction In Progress | - | - | 0.37 | 0.71 | 0.31 | 0.25 | Upgrade
|
| Leasehold Improvements | - | 2.01 | 1.98 | 1.74 | 1.74 | 1.73 | Upgrade
|
Updated May 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.